Clinical trial
Study to Investigate Which Clinical Risk Factors Are Considered by Physicians When Conducting Overall Febrile Neutropenia Risk Assessments for Patients Receiving Chemotherapy With an Intermediate (10% - 20%) Febrile Neutropenia Risk.
NCT01813721 is registered in ClinicalTrials.gov with Amgen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Study to Investigate Which Clinical Risk Factors Are Considered by Physicians When Conducting Overall Febrile Neutropenia Risk Assessments for Patients Receiving Chemotherapy With an Intermediate (10% - 20%) Febrile Neutropenia Risk.
- Lead sponsor
- Amgen
- Phase
- Observational
- Overall status
- Completed
- Start date
- December 31, 2012
- Completion date
- December 31, 2013
- Enrollment
- 1,007 (actual)
- Sites
- 90
Conditions
As the registry lists them; a condition with its own page is linked.